Transgene Presents New Pre-Clinical Data at AACR on (i) the Combination of TG4010 with Immune Checkpoint Inhibitors;(ii) TG3003, an Anti-CD115 Monoclonal Antibody

information fournie par Boursorama •21/04/2015 à 08:00

Strasbourg, France, April 21, 2015 – Transgene SA (Euronext: TNG) today announced that new pre-clinical data for two of its programs – TG4010 and TG3003 – were presented at the Annual Meeting of the American Association for Cancer Research (AACR) in Philadelphia, PA USA.

New pre-clinical data support potential combinations of TG4010 and immune checkpoint inhibitors
...
Data with TG3003 anti-CD115 monoclonal antibody support biological activity and differentiated mode of action
...

A third poster reviewing the clinical experience with Transgene’s MVA platform was also presented.

Copies of these posters can be found on Transgene’s website in the “Our Pipeline/Publications” section at http://www.transgene.fr/?page_id=10487#TG1050.